The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Relative to before the pandemic, the number of vaccinated participants fell 10% among children and 4% in adults in pandemic ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Candida auris is a dangerous fungal pathogen that has become a global health concern. It spreads easily in health care settings and can cause life-threatening infections, especially in patients with ...

Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...